13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D Filed 2026-10-16 Event 2026-10-08 SEC 0001829126-26-011242 →

SV Biotech Crossover Opportunities Fund LP → TRex Bio, Inc. TRXB

Stake: 7.00% Shares: 1,920,667 CUSIP: 89531N100 Class: Common Stock, par value $0.0001 per share

Item 4 — Purpose of Transaction

The Reporting Persons initially acquired the Preferred Stock underlying the Shares for investment purposes only. The Reporting Persons believe that the Issuer is an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their respective positions in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon completion of any of the actions discussed herein. The Reporting Persons intend to review their respective investments in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their respective investments in the Issuer as they deem appropriate including, without limitation, communicating with stockholders, management and the Board of Directors of the Issuer, engaging in discussions with third parties about the Issuer and the Reporting Persons' investment, making proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure, or operations of the Issuer, purchasing additional Shares, selling some or all of their Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, or changing their intention with respect to any and all matters referred to in Item 4.

Cross-References

Insider Activity (last 365d)
6 transactions
6 buys · 0 sales · 0 awards/exercises
Issuer Cluster
2 13D/G filings on this issuer
1 other filing besides this one
Filer Track Record
1 filings by this filer
0 other filings in the data moat
Short Interest
—
Not in latest FINRA snapshot

Form 4 Insider Transactions · last 365d

DateInsiderRoleTypeSharesPriceValue
2026-10-08 MARCUS JOEL S director Award 17,500 $14.00 $245K
2026-10-08 Coy Travis Alan director Award 17,500 $14.00 $245K
2026-10-08 Ross Michael Jay director Award 17,500 $14.00 $245K
2026-10-08 Hirth Peter director Award 17,500 $14.00 $245K
2026-10-08 Gallagher Carol Giltner director Award 17,500 $14.00 $245K
2026-10-08 Gilmore Julie Ann director Award 17,500 $14.00 $245K

Other 13D/G Filings on TRex Bio, Inc.

FiledFormFilerStakeShares
2026-10-16 SCHEDULE 13D ELI LILLY & Co 19.90% 5,480,872 view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →